Form 4: Amgen CEO Robert Bradway Reports Stock Disposals to Cover Tax Obligations
SEC Form 4 Filing
Amgen's CEO, Robert Bradway, reported the disposal of shares to cover tax obligations related to vested restricted stock units (RSUs).
Summary
- Robert A. Bradway, the Chairman, CEO, and President of Amgen Inc., filed a Form 4 detailing changes in his beneficial ownership of Amgen stock.
- On March 17, 2025, Bradway disposed of 12,853 shares of common stock at a price of $313.71 per share to satisfy tax obligations.
- Following the transaction, Bradway directly owns 587,565 shares of Amgen common stock.
- Bradway also indirectly owns 90,000 shares through a GRAT and 90,000 shares through a spousal GRAT.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for corporate insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 03/17/2025 | Date of the stock disposal transaction. |
Keywords
Form 4, Beneficial Ownership, Amgen, Bradway, Stock Disposal, Tax Obligations, Grat, RSUs
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.